DAFTAR PUSTAKA
Abbas, T. and Dutta, A. (2009) ‘p21 in cancer: intricate networks and multiple activities’, Nature Reviews Cancer, 9(6), pp. 400–414. Available at:
https://doi.org/10.1038/nrc2657.
Abdelaal, S.E., Habib, F.M., Hassan, N.S. and Ibrahim, N.A. (2016) ‘MDM2 Expression in Serous and Mucinous Epithelial Tumours of the Ovary’, p. 6.
Babaier, A. and Ghatage, P. (2020) ‘Mucinous Cancer of the Ovary: Overview and Current Status’, Diagnostics, 10(1), p. 52. Available at:
https://doi.org/10.3390/diagnostics10010052.
Bandera, E.V., Lee, V.S., Qin, B., Rodriguez-Rodriguez, L., Powell, C.B. and Kushi, L.H.
(2017) ‘Impact of body mass index on ovarian cancer survival varies by stage’, British Journal of Cancer, 117(2), pp. 282–289. Available at:
https://doi.org/10.1038/bjc.2017.162.
Banno, K., Yanokura, M., Iida, M., Masuda, K. and Aoki, D. (2014) ‘Carcinogenic mechanisms of endometrial cancer: Involvement of genetics and epigenetics:
Carcinogenesis of endometrial cancer’, Journal of Obstetrics and Gynaecology Research, 40(8), pp. 1957–1967. Available at: https://doi.org/10.1111/jog.12442.
Boffetta, P. and Hainaut, P. (eds) (2019) Encyclopedia of Cancer. 3rd edition. Amsterdam Boston Heidelberg London: Elsevier, Academic Press.
Bohlman, S. and Manfredi, J.J. (2014) ‘p53-Independent Effects of Mdm2’, in S.P. Deb and S. Deb (eds) Mutant p53 and MDM2 in Cancer. Dordrecht: Springer Netherlands (Subcellular Biochemistry), pp. 235–246. Available at:
https://doi.org/10.1007/978-94-017-9211-0_13.
Bosch, I. (2000) ‘Identification of differentially expressed genes from limited amounts of RNA’, Nucleic Acids Research, 28(7), pp. 27e–227. Available at:
https://doi.org/10.1093/nar/28.7.e27.
Budiana, I.N.G., Angelina, M. and Pemayun, T.G.A. (2019) ‘Ovarian cancer:
Pathogenesis and current recommendations for prophylactic surgery’, Journal of the Turkish-German Gynecological Association, 20(1), pp. 47–54. Available at:
https://doi.org/10.4274/jtgga.galenos.2018.2018.0119.
Chesang, J.J. (2017) ‘Pathogenesis Of Ovarian Cancer: Current Perspectives’, East African Medical Journal, p. 14.
De Leo, A., Santini, D., Ceccarelli, C., Santandrea, G., Palicelli, A., Acquaviva, G., Chiarucci, F., Rosini, F., Ravegnini, G., Pession, A., Turchetti, D., Zamagni, C., Perrone, A.M., De Iaco, P., Tallini, G. and De Biase, D. (2021) ‘What Is New on Ovarian Carcinoma: Integrated Morphologic and Molecular Analysis Following the New 2020 World Health Organization Classification of Female Genital Tumors’,
Diagnostics, 11(4), p. 697. Available at:
https://doi.org/10.3390/diagnostics11040697.
Donzelli, S., Fontemaggi, G., Fazi, F., Di Agostino, S., Padula, F., Biagioni, F., Muti, P., Strano, S. and Blandino, G. (2012) ‘MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function’, Cell Death &
Differentiation, 19(6), pp. 1038–1048. Available at:
https://doi.org/10.1038/cdd.2011.190.
Engeland, K. (2022) ‘Cell cycle regulation: p53-p21-RB signaling’, Cell Death &
Differentiation, 29(5), pp. 946–960. Available at: https://doi.org/10.1038/s41418- 022-00988-z.
Felix, A.S., Sherman, M.E., Hewitt, S.M., Gunja, M.Z., Yang, H.P., Cora, R.L., Boudreau, V., Ylaya, K., Lissowska, J., Brinton, L.A. and Wentzensen, N. (2015) ‘Cell-Cycle Protein Expression in a Population-Based Study of Ovarian and Endometrial Cancers’, Frontiers in Oncology, 5. Available at:
https://doi.org/10.3389/fonc.2015.00025.
Gasparri, M., Bardhi, E., Ruscito, I., Papadia, A., Farooqi, A., Marchetti, C., Bogani, G., Ceccacci, I., Mueller, M. and Benedetti Panici, P. (2017) ‘PI3K/AKT/mTOR Pathway in Ovarian Cancer Treatment: Are We on the Right Track?’, Geburtshilfe und Frauenheilkunde, 77(10), pp. 1095–1103. Available at:
https://doi.org/10.1055/s-0043-118907.
Georgakilas, A.G., Martin, O.A. and Bonner, W.M. (2017) ‘p21: A Two-Faced Genome Guardian’, Trends in Molecular Medicine, 23(4), pp. 310–319. Available at:
https://doi.org/10.1016/j.molmed.2017.02.001.
Guo, T., Dong, X., Xie, S., Zhang, Ling, Zeng, P. and Zhang, Lin (2021) ‘Cellular Mechanism of Gene Mutations and Potential Therapeutic Targets in Ovarian Cancer’, Cancer Management and Research, Volume 13, pp. 3081–3100. Available at: https://doi.org/10.2147/CMAR.S292992.
Hernandez‐Monge, J., Martínez‐Sánchez, M., Rousset‐Roman, A., Medina‐Medina, I.
and Olivares‐Illana, V. (2021) ‘MDM2 regulates RB levels during genotoxic stress’, EMBO reports, 22(1), p. e50615. Available at:
https://doi.org/10.15252/embr.202050615.
Hong, L., Wang, Y., Chen, W. and Yang, S. (2018) ‘MicroRNA‐508 suppresses epithelial‐
mesenchymal transition, migration, and invasion of ovarian cancer cells through the MAPK1/ERK signaling pathway’, Journal of Cellular Biochemistry, 119(9), pp. 7431–7440. Available at: https://doi.org/10.1002/jcb.27052.
Inaba, K., Oda, K., Aoki, K., Sone, K., Ikeda, Y., Miyasaka, A., Kashiyama, T., Fukuda, T., Makii, C., Arimoto, T., Wada-Hiraike, O., Kawana, K., Yano, T., Osuga, Y. and Fujii, T. (2016) ‘Synergistic antitumor effects of combination PI3K/mTOR and MEK inhibition (SAR245409 and pimasertib) in mucinous ovarian carcinoma cells by fluorescence resonance energy transfer imaging’, Oncotarget, 7(20), pp. 29577–
29591. Available at: https://doi.org/10.18632/oncotarget.8807.
Karimian, A., Ahmadi, Y. and Yousefi, B. (2016) ‘Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage’, DNA Repair, 42, pp.
63–71. Available at: https://doi.org/10.1016/j.dnarep.2016.04.008.
Ke, X., Li, L., Li, J., Zheng, M. and Liu, P. (2022) ‘Anti‐oncogenic PTEN induces ovarian cancer cell senescence by targeting P21’, Cell Biology International, 46(1), pp.
118–128. Available at: https://doi.org/10.1002/cbin.11709.
Köbel, M. and Kang, E.Y. (2022) ‘The Evolution of Ovarian Carcinoma Subclassification’, Cancers, 14(2), p. 416. Available at:
https://doi.org/10.3390/cancers14020416.
Kotsopoulos, J., Moody, J.R.K., Fan, I., Rosen, B., Risch, H.A., McLaughlin, J.R., Sun, P. and Narod, S.A. (2012) ‘Height, weight, BMI and ovarian cancer survival’, Gynecologic Oncology, 127(1), pp. 83–87. Available at:
https://doi.org/10.1016/j.ygyno.2012.05.038.
Kreis, Louwen, and Yuan (2019) ‘The Multifaceted p21 (Cip1/Waf1/CDKN1A) in Cell Differentiation, Migration and Cancer Therapy’, Cancers, 11(9), p. 1220. Available at: https://doi.org/10.3390/cancers11091220.
Kuang, J., Yan, X., Genders, A.J., Granata, C. and Bishop, D.J. (2018) ‘An overview of technical considerations when using quantitative real-time PCR analysis of gene expression in human exercise research’, PLOS ONE. Edited by R. Kalendar, 13(5), p. e0196438. Available at: https://doi.org/10.1371/journal.pone.0196438.
Kurman, R.J. and Shih, I.-M. (2016) ‘The Dualistic Model of Ovarian Carcinogenesis’, The American Journal of Pathology, 186(4), pp. 733–747. Available at:
https://doi.org/10.1016/j.ajpath.2015.11.011.
Lee, Y.-J., Lee, M.-Y., Ruan, A., Chen, C.-K., Liu, H.-P., Wang, C.-J., Chao, W.-R. and Han, C.-P. (2016) ‘Multipoint Kras oncogene mutations potentially indicate mucinous carcinoma on the entire spectrum of mucinous ovarian neoplasms’, Oncotarget, 7(50), pp. 82097–82103. Available at:
https://doi.org/10.18632/oncotarget.13449.
Mackenzie, R., Kommoss, S., Winterhoff, B.J., Kipp, B.R., Garcia, J.J., Voss, J., Halling, K., Karnezis, A., Senz, J., Yang, W., Prigge, E.-S., Reuschenbach, M., Doeberitz, M.V.K., Gilks, B.C., Huntsman, D.G., Bakkum-Gamez, J., McAlpine, J.N. and Anglesio, M.S. (2015) ‘Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms’, BMC Cancer, 15(1), p. 415. Available at:
https://doi.org/10.1186/s12885-015-1421-8.
Makii, C., Ikeda, Y., Oda, K., Uehara, Y., Nishijima, A., Koso, T., Kawata, Y., Kashiyama, T., Miyasaka, A., Sone, K., Tanikawa, M., Tsuruga, T., Mori-Uchino, M., Nagasaka, K., Matsumoto, Y., Wada-Hiraike, O., Kawana, K., Hasegawa, K., Fujiwara, K., Aburatani, H., Osuga, Y. and Fujii, T. (2019) ‘Anti-tumor activity of dual inhibition of phosphatidylinositol 3-kinase and MDM2 against clear cell ovarian carcinoma’, Gynecologic Oncology, 155(2), pp. 331–339. Available at:
https://doi.org/10.1016/j.ygyno.2019.08.028.
Makii, C., Oda, K., Ikeda, Y., Sone, K., Hasegawa, K., Uehara, Y., Nishijima, A., Asada, K., Koso, T., Fukuda, T., Inaba, K., Oki, S., Machino, H., Kojima, M., Kashiyama, T., Mori-Uchino, M., Arimoto, T., Wada-Hiraike, O., Kawana, K., Yano, T.,
Fujiwara, K., Aburatani, H., Osuga, Y. and Fujii, T. (2016) ‘MDM2 is a potential therapeutic target and prognostic factor for ovarian clear cell carcinomas with wild type TP53’, Oncotarget, 7(46), pp. 75328–75338. Available at:
https://doi.org/10.18632/oncotarget.12175.
Minagawa, Y., Ishino, K., Wada, R., Kudo, M., Naito, Z., Takeshita, T. and Ohashi, R.
(2020) ‘High Expression of p21 as a Potential Therapeutic Target in Ovarian Clear- cell Carcinoma’, Anticancer Research, 40(10), pp. 5631–5639. Available at:
https://doi.org/10.21873/anticanres.14576.
Mogensen, J.B., Kjær, S.K., Mellemkjær, L. and Jensen, A. (2016) ‘Endometriosis and risks for ovarian, endometrial and breast cancers: A nationwide cohort study’, Gynecologic Oncology, 143(1), pp. 87–92. Available at:
https://doi.org/10.1016/j.ygyno.2016.07.095.
Momenimovahed, Z., Tiznobaik, A., Taheri, S. and Salehiniya, H. (2019) ‘Ovarian cancer in the world: epidemiology and risk factors’, International Journal of Women’s Health, Volume 11, pp. 287–299. Available at:
https://doi.org/10.2147/IJWH.S197604.
Poole, E.M., Merritt, M.A., Jordan, S.J., Yang, H.P., Hankinson, S.E., Park, Y., Rosner, B., Webb, P.M., Cramer, D.W., Wentzensen, N., Terry, K.L. and Tworoger, S.S.
(2013) ‘Hormonal and Reproductive Risk Factors for Epithelial Ovarian Cancer by Tumor Aggressiveness’, Cancer Epidemiology, Biomarkers & Prevention, 22(3), pp. 429–437. Available at: https://doi.org/10.1158/1055-9965.EPI-12-1183-T.
Rechsteiner, M., Zimmermann, A.-K., Wild, P.J., Caduff, R., Von Teichman, A., Fink, D., Moch, H. and Noske, A. (2013) ‘TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type’, Experimental and Molecular Pathology, 95(2), pp. 235–241.
Available at: https://doi.org/10.1016/j.yexmp.2013.08.004.
Ricci, F., Affatato, R., Carrassa, L. and Damia, G. (2018) ‘Recent Insights into Mucinous Ovarian Carcinoma’, International Journal of Molecular Sciences, 19(6), p. 1569.
Available at: https://doi.org/10.3390/ijms19061569.
Rinne, N., Christie, E.L., Ardasheva, A., Kwok, C.H., Demchenko, N., Low, C., Tralau- Stewart, C., Fotopoulou, C. and Cunnea, P. (2021) ‘Targeting the PI3K/AKT/mTOR pathway in epithelial ovarian cancer, therapeutic treatment options for platinum-resistant ovarian cancer’, Cancer Drug Resistance [Preprint].
Available at: https://doi.org/10.20517/cdr.2021.05.
Shaikh, M.F., Morano, W.F., Lee, J., Gleeson, E., Babcock, B.D., Michl, J., Sarafraz- Yazdi, E., Pincus, M.R. and Bowne, W.B. (2016) ‘Emerging Role of MDM2 as Target for Anti-Cancer Therapy: A Review’, Annals of Clinical and Laboratory Science, 46(6), pp. 627–634.
Skirnisdottir, I. and Seidal, T. (2013) ‘Association of p21, p21 p27 and p21 p53 Status to Histological Subtypes and Prognosis in Low-stage Epithelial Ovarian Cancer’, CANCER GENOMICS, p. 8.
Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A. and Bray, F. (2021) ‘Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries’, CA: A Cancer Journal for Clinicians, 71(3), pp. 209–249. Available at: https://doi.org/10.3322/caac.21660.
Sung, P.-L., Chang, Y.-H., Chao, K.-C. and Chuang, C.-M. (2014) ‘Global distribution pattern of histological subtypes of epithelial ovarian cancer: A database analysis and systematic review’, Gynecologic Oncology, 133(2), pp. 147–154. Available at:
https://doi.org/10.1016/j.ygyno.2014.02.016.
Therachiyil, L., Anand, A., Azmi, A., Bhat, A., Korashy, H.M. and Uddin, S. (2022) ‘Role of RAS signaling in ovarian cancer’, F1000Research, 11, p. 1253. Available at:
https://doi.org/10.12688/f1000research.126337.1.
Wang, S., Zhao, Y., Aguilar, A., Bernard, D. and Yang, C.-Y. (2017) ‘Targeting the MDM2–p53 Protein–Protein Interaction for New Cancer Therapy: Progress and Challenges’, Cold Spring Harbor Perspectives in Medicine, 7(5), p. a026245.
Available at: https://doi.org/10.1101/cshperspect.a026245.
Wu, P.-K., Becker, A. and Park, J.-I. (2020) ‘Growth Inhibitory Signaling of the Raf/MEK/ERK Pathway’, International Journal of Molecular Sciences, 21(15), p.
5436. Available at: https://doi.org/10.3390/ijms21155436.
Xu, W., Rush, J., Rickett, K. and Coward, J.I.G. (2016) ‘Mucinous ovarian cancer: A therapeutic review’, Critical Reviews in Oncology/Hematology, 102, pp. 26–36.
Available at: https://doi.org/10.1016/j.critrevonc.2016.03.015.
Yu, Q., Li, Y., Mu, K., Li, Z., Meng, Q., Wu, X., Wang, Y. and Li, L. (2014) ‘Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations’, Diagnostic Pathology, 9(1), p. 71. Available at:
https://doi.org/10.1186/1746-1596-9-71.
Yue, X., Zhao, Y., Xu, Y., Zheng, M., Feng, Z. and Hu, W. (2017) ‘Mutant p53 in Cancer:
Accumulation, Gain-of-Function, and Therapy’, Journal of Molecular Biology, 429(11), pp. 1595–1606. Available at: https://doi.org/10.1016/j.jmb.2017.03.030.
Zhao, Y., Yu, H. and Hu, W. (2014) ‘The regulation of MDM2 oncogene and its impact on human cancers’, Acta Biochimica et Biophysica Sinica, 46(3), pp. 180–189.
Available at: https://doi.org/10.1093/abbs/gmt147.
